Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% dose-escalation study in mild to moderate Alzheimer's disease
ISRCTN64846759Phase 2Completed
- Sponsor
- Octapharma
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of Human normal immunoglobulin G in Alzheimer's disease (AD) (7 arms), sponsored by Octapharma. Primary endpoint: Change in total amyloid beta in CNS and plasma after 24 weeks. Started Feb 2009; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ISRCTN64846759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64846759.